ADAKVEO® (crizanlizumab-tmca) for Sickle Cell Pain Crises
What is ADAKVEO ® (crizanlizumab-tmca)? ADAKVEO is a prescription medicine used in people 16 years of age and older who have sickle cell disease to help reduce how often painful crises happen. It is not known if ADAKVEO is safe and effective in children under 16 years of age...
FDA approves first targeted therapy to treat patients with painful ...
Today, the U.S. Food and Drug Administration approved Adakveo (crizanlizumab-tmca), a treatment to reduce the frequency of vaso-occlusive crisis – a common and painful complication of sickle cell...
ADAKVEO is a selectin blocker indicated to reduce the frequency of vasoocclusive crises in adults and pediatric patients aged 16 years and older with sickle cell disease.
Crizanlizumab - Wikipedia
Crizanlizumab, sold under the brand name Adakveo among others, is a monoclonal antibody medication that binds to P-selectin. [3] It is a medication used to reduce the frequency of vaso-occlusive crisis in people aged 16 years and older who have sickle cell anemia .
FDA approves crizanlizumab-tmca for sickle cell disease
On November 15, 2019, Food and Drug Administration approved crizanlizumab-tmca (ADAKVEO, Novartis) to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16...
镰状细胞病新药Adakveo获欧盟批准，用于预防血管阻塞危象
2020年11月2日 · 近日，诺华（Novartis）宣布，欧盟委员会（EC）已批准Adakveo（crizanlizumab-tmca），用于年龄≥16岁的镰状细胞病（SCD）成人和儿科患者，预防复发性血管阻塞性危象（VOC）或疼痛危象。
Adakveo (crizanlizumab-ymca): Uses, Side Effects, Interactions ... - WebMD
2025年3月10日 · Overview: Adakveo is used to help reduce how often pain crises happen in people with sickle cell disease. It is injected into a vein (IV) by a health care provider. Common side effects include...
Adakveo: Uses, Side Effects, Warnings - Drugs.com
2024年10月16日 · Adakveo (crizanlizumab-tmca) is used for the prevention of vasoocclusive crises (VOCs) in patients with sickle cell disease (SCD). Includes Adakveo side effects, interactions and indications.
New Novartis medicine Adakveo® (crizanlizumab) approved by …
2019年11月15日 · Adakveo ® (crizanlizumab) – previously known as SEG101 – is indicated to reduce the frequency of VOCs, or pain crises, in adults and pediatric patients aged 16 years and older with sickle cell disease.
镰状细胞病 (SCD)创新药！诺华P-选择素抑制剂Adakveo获欧盟批 …
2020年10月31日 · Adakveo是第一个被批准用于SCD患者预防血管阻塞性危象 (VOC)的靶向疗法。 2020年10月31日讯 / 生物谷 BIOON/ -- 诺华 （Novartis）近日宣布，欧盟委员会（EC）已批准Adakveo（crizanlizumab），用于年龄≥16岁的镰状细胞病（SCD）成人和儿科患者，预防复发性血管阻塞性危象（VOC）或疼痛危象。 Adakveo可作为羟基脲（HU/HC）的附加疗法，也可作为单药疗法用于HU/HC不适合或应答不足的患者。